Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): Intergroup trial N9741 in first-line treatment of metastatic colorectal cancer

Cancer

Volumn 110, Issue 3, 2007, Pages 670-677

  Ashley, Amanda C ^a   Sargent, Daniel J ^a   Alberts, Steven R ^a   Grothey, Axel ^a   Campbell, Megan E ^a   Morton, Roscoe F ^b   Fuchs, Charles S ^c   Ramanathan, Ramesh K ^d   Williamson, Stephen K ^e   Findlay, Brian P ^f   Pitot, Henry C ^a   Goldberg, Richard M ^g  

^a MAYO CLINIC   (United States)

^b Iowa Oncology Research Association CCOP   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f Institut national du cancer du Canada   (Canada)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Clinical trial; Irinotecan; Metastatic colorectal cancer; Oxaliplatin

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DYSESTHESIA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NEUROTOXICITY; NEUTROPENIA; ORAL DYSESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34547097252     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22831     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Falcone A, Masi G, Brunetti I, et al. The triplet combination of irinotecan, oxaliplatin and 5FU/leucovorin (FOL-FOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings Part I.) 2006;24:149s. Abstract 3513.
3. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22:23-30.
4. Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005;16:425-429.
5. th ed. Philadelphia: Lippincott Williams & Wilkins; 2006:371-413.
6. Wasserman E, Cuvier C, Lokeic F, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol. 1999;17:1751-1759.
7. Scheithauer W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol. 1999;17:902-906.
8. Andre SD, Sargent DJ, Cha SS, et al. 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a North Central Cancer Treatment Group Study. Clin Colorectal Cancer. 2005;4:325-331.
9. Sargent DR, Goldberg R, Jacobson S, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091-1097.
10. McLeod HL, Parodi L, Sargent DJ, et al. UGT1A1*28, toxicity and outcome in advanced colorectal cancer: results from trial N9741 [abstract]. J Clin Oncol. 2006;24:151s. Abstract 3520.
11. Golfinopoulos V, Pentheroudakis G, Pavlidis N. Treatment of colorectal cancer in the elderly: a review of the literature. Cancer Treat Rev. 2006;32:1-8.
12. Kohne CH, Grothey A, Bokemeyer C, et al. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol. 2001;12:435-442.
13. Rothenberg M, Cox J, DeVore R, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999;85:786-795.
14. Chau I, Norman AR, Cunningham D, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Brit J Cancer. 2004;91:1453-1458.
15. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085-4091.
16. Haller DG, Rothenberg ML, Wong AO, et al. Final results of a randomized phase III trial comparing irinotecan plus oxaliplatin (IROX) to irinotecan monotherapy in patients with metastatic colorectal cancer (MCRC) previously treated with fluoropyrimidines [abstract]. Ann Oncol. 2004;15:(suppl 3):iii70. Abstract 263O.
17. Schalhorn A, Fischer von Weikersthal L, Quietzsch D, et al. Phase III trial of irinotecan plus 5-FU/folinic acid (FOL-FIRI) as first-line treatment of metastatic colorectal cancer (CRC): the FIRE-TRIAL [abstract]. Proc GI Cancer Symposium 2006. Abstract 281. Available at: http://www.asco.org/ portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 41&abstractID=149. Accessed January 2006.
18. Souglakos J, Syrigos K, Potamianou A, et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol. 2004;15:1204-1209.